Schering-Plough: UK trial shows Aerius causes less drowsiness than Xyzal

Pharmaceutical Company Product News

Schering-Plough has announced that data published in the October issue of Drug Safety has revealed that the use of Aerius/Neoclarityn (desloratadine) to treat allergic rhinitis results in less chance of drowsiness than for Xyzal (levocetirizine).

The trial of 24,000 UK patients by Drug Safety Research Unit, backed by a grant from Schering-Plough, found that the incidence of drowsiness in patients using Xyzal was six times greater than those using Aerius/Neoclarityn.

Aerius/Neoclarityn is a prescription antihistamine that is non-sedating. It is indicated for the treatment of allergic rhinitis, chronic idiopathic urticaria and hives.

Anthony Frew, professor of allergy and respiratory medicine at Brighton & Sussex Medical School, said: "Side effects such as drowsiness and sedation can be key issues for allergic rhinitis patients, especially during the day."

He added that potential side effects should always be taken into account when considering which treatment is most appropriate for each patient.

In February, Schering-Plough announced the Food and Drug Authority approval for Clarinex-D 12 Hour (desloratadine 2.5mg/pseudoephedrine 120mg), a prescription antihistamine treatment with decongestant for patients with seasonal allergies.

The treatment uses a bi-layer delivery system and is recommended for twice-daily dosing for control of nasal congestion and other allergic symptoms.

See all the latest jobs in Pharmaceutical
Return to news